Journal
CANCER CELL
Volume 31, Issue 3, Pages 368-382Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2017.02.003
Keywords
-
Categories
Funding
- NIH/NCI [2P01CA098912]
- Board of Governors Cancer Research Chair
- Steven Spielberg Fund in Prostate Cancer Research
- US Department of Defense PCRP grant [W81XWH-15-1-0493]
Ask authors/readers for more resources
Metastasis is a predominant cause of death for prostate cancer (PCa) patients; however, the underlying mechanisms are poorly understood. We report that monoamine oxidase A (MAOA) is a clinically and functionally important mediator of PCa bone and visceral metastases, activating paracrine Shh signaling in tumor-stromal interactions. MAOA provides tumor cell growth advantages in the bone microenvironment by stimulating interleukin-6 (IL6) release from osteoblasts, and triggers skeletal colonization by activating osteoclastogenesis through osteoblast production of RANKL and IL6. MAOA inhibitor treatment effectively reduces metastasis and prolongs mouse survival by disengaging the Shh-IL6-RANKL signaling network in stromal cells in the tumor microenvironment. These findings provide a rationale for targeting MAOA and its associated molecules to treat PCa metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available